‫ גסטרואנטרולוגיה‬- 2011 ‫מאמרי חובה לבחינה מועד‬
1. Mini-Reviews and Perspectives: Intraductal papillary mucinous neoplasms of the
pancreas. Fernández-del Castillo C, Adsay NV. Gastroenterology. 2010
Sep;139(3):708-13
2. Antidiabetic therapies affect risk of pancreatic cancer. Li D, Yeung SC, Hassan
MM, Konopleva M, Abbruzzese JL. Gastroenterology. 2009 Aug;137(2):482-8
Editorial: Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?
Yu–Xiao Yang; Gastroenterology. 2009 Aug;137(2):412-5
3. Preoperative biliary drainage for cancer of the head of the pancreas. van der Gaag
NA, Rauws EA, van Eijck CH, et al. N Engl J Med. 2010 Jan 14; 362(2):129-37.
Editorial: Preoperative Biliary Stents in Pancreatic Cancer — Proceed with Caution.
Todd H. Baron, M.D., and Richard A. Kozarek, M.D. N Engl J Med. 2010 Jan 14;
362(2):170-32.
4. AASLD PRACTICE GUIDELINE. Management of Hepatocellular Carcinoma: An
Update. Jordi Bruix and Morris Sherman; Hepatology March 2011; 1020-1022
5. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection;
European Association for the Study of the Liver EASL guidelines. Journal of
Hepatology 2011(55); 245-464
6. The London Position Statement of the World Congress of Gastroenterology on
Biological Therapy for IBD with the European Crohn's and Colitis Organization: when
to start, when to stop, which drug to choose, and how to predict response? D'Haens
GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB,
Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A,
Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C,
Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.; Am J
Gastroenterol. 2011 Feb;106(2):199-212
7. Management of ingested foreign bodies and food impactions. Guidelines for foreign
body; Gastrointestinal Endoscopy Volume 73, No. 6 : 2011 ;1085-1091
8. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory
bowel diseases. Chassaing B, Darfeuille-Michaud A. Gastroenterology. 2011
May;140(6):1720-28.
9. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.
Strober W, Fuss IJ. Gastroenterology. 2011 May;140(6):1756-67. Review.
10. Risk factors for idiosyncratic drug-induced liver injury. Chalasani N, Björnsson E.;
Gastroenterology. 2010 Jun;138(7):2246-59. Review
11. Telaprevir for Retreatment of HCV Infection. Stefan Zeuzem, M.D., Pietro Andreone,
M.D., Stanislas Pol, M.D., Eric Lawitz, M.D., Moises Diago, M.D., Stuart Roberts,
M.D., Roberto Focaccia, M.D., Zobair Younossi, M.D., Graham R. Foster, F.C.R.P.,
Andrzej Horban, M.D., Peter Ferenci, M.D., Frederik Nevens, M.D., Beat Müllhaupt,
M.D., Paul Pockros, M.D., Ruben Terg, M.D., Daniel Shouval, M.D., Bart van Hoek,
M.D., Ola Weiland, M.D., Rolf Van Heeswijk, Pharm.D., Sandra De Meyer, Ph.D.,
Don Luo, Ph.D., Griet Boogaerts, M.Sc., Ramon Polo, Pharm.D., Gaston Picchio,
Ph.D., and Maria Beumont, M.D. for the REALIZE Study Team; N Engl J Med 2011;
364: 2417-2428 June 23
12. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. Ira M.
Jacobson, M.D., John G. McHutchison, M.D., Geoffrey Dusheiko, M.D., Adrian M. Di
Bisceglie, M.D., K. Rajender Reddy, M.D., Natalie H. Bzowej, M.D., Patrick Marcellin,
M.D., Andrew J. Muir, M.D., Peter Ferenci, M.D., Robert Flisiak, M.D., Jacob George,
M.D., Mario Rizzetto, M.D., Daniel Shouval, M.D., Ricard Sola, M.D., Ruben A. Terg,
M.D., Eric M. Yoshida, M.D., Nathalie Adda, M.D., Leif Bengtsson, B.Sc., Abdul J.
Sankoh, Ph.D., Tara L. Kieffer, Ph.D., Shelley George, M.D., Robert S. Kauffman,
M.D., Ph.D., and Stefan Zeuzem M.D. for the ADVANCE Study Team; N Engl J Med
2011; 364:2405-2416June 23, 2011
13. Maria Y. Ho, Charles D. Blanke. Mini reviews & perspectives - Gastrointestinal
Stromal Tumors: Disease and Treatment Update ; Gastroenterology May 2011
140:1372-5
14. Hepatitis delta virus. Hughes SA, Wedemeyer H, Harrison PM. Lancet. 2011 Jul
2;378(9785):73-85.
15. Helicobacter pylori treatment in the era of increasing antibiotic resistance. David Y
Graham , Lori Fischbach; Gut 2010 ;59; 1143-1153
16. Crohn's disease susceptibility gene interactions, a NOD to the newcomer ATG16L1.
Cadwell K. Gastroenterology. 2010 Nov;139(5):1448-50.